A Phase 2 interventional study of Tipranavir (TPV) low dose and Tipranavir (TPV) high dose in HIV Infections, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in HIV Infections by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. HIV Infections · Boehringer Ingelheim.
Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 24th largest by enrollment of the 46 interventional ones that give a count, is one of 8 that started in 1999, is one of 12 in phase 2, and was the 64th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 67 studies in HIV Infections by Boehringer Ingelheim is open now. The open studies under HIV Infections, anywhere →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 13 · Phase 4 7
First in 1998; this study’s year is marked. 8 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is close to the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 46 interventional studies, 256 across the 16 observational. Of the 62 that completed or were terminated, 24 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 67 studies in HIV Infections by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two different doses of TPV in combination with RTV for efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tipranavir (TPV) low dose · Drug: Ritonavir low dose
Drug: Tipranavir (TPV) high dose · Drug: Ritonavir low dose
Drug: Ritonavir high dose · Drug: Saquinavir
Change from baseline in plasma HIV-1 RNA concentrations
Time frame: Week 16, 24 and 48
Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ)
using the Roche Amplicor HIV Monitor™ Method \[limit of detection (LD) 400 copies/mL\] and the Roche Amplicor UltraSensitive Method™ (LD 50 copies/mL)
Time frame: up to 96 weeks
Number of patients with treatment-emergent and drug-related adverse events (AEs)
Time frame: up to 96 weeks
Number of patients with serious adverse events (SAEs)
Time frame: up to 96 weeks
Number of patients with grade 3 and 4 laboratory abnormalities
Time frame: up to 96 weeks
Change from baseline in cluster of differentiation (CD) 4+ cell count
Time frame: Week 16, 24 and 48
Time to virologic failure
defined as plasma HIV-1 RNA values \>400 copies/mL at two consecutive time points 2 to 4 weeks apart
Time frame: after week 16
Occurrence of new or recurring AIDS-defining illnesses
Time frame: up to 96 weeks
Occurrence of HIV-1 related illness
Time frame: up to 96 weeks
Occurrence of death
Time frame: up to 96 weeks
Time to new or recurring AIDS-defining illnesses
Time frame: up to 96 weeks
Time to HIV-1 related illness
Time frame: up to 96 weeks
Time to death
Time frame: up to 96 weeks
Change from baseline in blood glucose
Time frame: up to 96 weeks
Change from baseline in cholesterol
Time frame: up to 96 weeks
Change from baseline in high density lipoprotein (HDL)
Time frame: up to 96 weeks
Change from baseline in triglycerides
Time frame: up to 96 weeks
Time to virologic response
Time frame: up to 96 weeks
Trough plasma tipranavir concentrations
Time frame: up to week 24
Sequence-based HIV-1 analysis (genotyping) and drug susceptibility assays (phenotyping)
Time frame: Baseline and week 24
No study locations are listed for this record.
The record gives a start of Dec 1999 and a primary completion of Nov 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.